SCIREX Celebrates 10 Years of Leadership in Clinical Research

Share Article

SCIREX Corporation, a leader in the delivery of drug development services to the global pharmaceutical and biotechnology industries, this month celebrates the 10th anniversary of its incorporation.

SCIREX Corporation, a leader in the delivery of drug development services to the global pharmaceutical and biotechnology industries, this month celebrates the 10th anniversary of its incorporation. In February1996, Biomedical Research Group and National Medical Research Corporation merged to form what is now known as SCIREX Corporation. Since that time, SCIREX has become the premier provider of clinical research services for Analgesia and Central Nervous System disorders.

In a message to the company marking the milestone, CEO James Utterback thanked employees for their contributions to the success of the enterprise and of its clients. “We go past our 10th Anniversary with many goals and opportunities ahead of us…I am proud to be a part of this company's history and future. You, too, should fill with pride when you consider how important each of your contributions are to improving health and bringing new medications to the global marketplace.”

SCIREX now helps clients address every phase of drug development process, including full Phase I-IV clinical research, early development services, and post-marketing solutions. Additionally, in 2005 SCIREX expanded operations farther into Europe with the opening of its Poland office and formed strategic partnerships with Clinigene/Biocon Ltd. in India and GleneaglesCRC in Singapore.

SCIREX now has offices in Philadelphia, Chicago, San Diego, Austin, Salt Lake City, Tampa, Hartford, London and Krakow. Its 450+ employees have conducted more than 1,000 studies involving more than 130,000 patients. Approximately 80% of its clients are drawn from emerging and mid-tier Pharma and Biotech while the remainder includes some of the largest global pharmaceutical companies in the industry. Regardless of growth, Utterback observed that “therapeutic focus, scientific expertise, and quality will continue to guide our efforts.”

“Ultimately, the measure of our success,” added Utterback, “will be continuous improvement in each of four key metrics: client satisfaction, employee satisfaction, project team performance, and financial performance. Moving forward, we will continue to practice a passionate focus on quality and client satisfaction, to bring our clients the best in class services they have come to expect from SCIREX.”

SCIREX Corporation (http://www.scirex.com) is an industry leader in the delivery of Phase I-IV drug development services to the global pharmaceutical and biotechnology industry. SCIREX provides clinical trial management, drug development planning, protocol design, submission services, regulatory affairs consulting, investigator and patient recruitment, data management, statistics, medical writing and offers an array of technology solutions including IVRS, EDC and SIMSTM (Study Information Management System). SCIREX brings experience from more than 1,000 clinical trials involving well over 130,000 patients in most major therapeutic areas, with specific expertise in pain and inflammation, and neurological and psychiatric disorders. SCIREX is a wholly-owned subsidiary of Omnicom Group, Inc. (NYSE: OMC) (http://www.omnicomgroup.com).

For more information contact Blythe Vito, SCIREX Corporate Marketing at (215) 907-1330 x1054, or visit http://www.scirex.com.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Blythe Vito